The Gastrointestinal Market Outlook to 2012

Table of Contents

Executive Summary

• Patient potential of GIT therapeutic area
• Global market analysis
• Pipeline analysis
• Competitive landscape

Chapter 1 Patient potential of GIT

• therapeutic area
• Summary
• Introduction
• Gastroesophageal reflux disorder
• Overview
• Diagnosis, treatment and management
• Epidemiology
• Forecast epidemiology
• Peptic ulcer disease
• Overview
• Diagnosis, treatment and management
• Epidemiology
• Forecast epidemiology
• Irritable bowel syndrome
• Overview
• Diagnosis, treatment and management
• Epidemiology
• Ulcerative colitis
• Overview
• Diagnosis, treatment and management
• Epidemiology
• Forecast epidemiology
• Crohn' s disease
• Overview
• Diagnosis, treatment and management
• Epidemiology
• Forecast epidemiology

Chapter 2 Global market analysis

• Summary
• Introduction
• Market analysis by country
• Licensing trends
• Market analysis by drug class
• Leading brand dynamics
• Key events in the GIT market
• Gastroesophageal reflux disorder and peptic ulcer disease
• Leading brands of the GERD/PUD market
• Proton pump inhibitor market analysis
  • Market dynamics
  • Key brands analysis
• Histamine-2 receptor antagonist market analysis
  • Market dynamics
  • Key brands analysis
• GERD/PUD sales forecasts to 2012
• Irritable bowel syndrome
• Competitive dynamics of IBS subclasses
• Leading brands of the IBS market
• GI sensorimotor modulators market analysis
  • Market dynamics
  • Key brands analysis
  • Antispasmodics/anticholinergics
  • Market dynamics
• IBS sales forecasts to 2012
• Inflammatory bowel disease: Crohn' s disease and ulcerative colitis
• Competitive dynamics of Crohn' s disease and ulcerative colitis subclasses
• Leading brands of IBD subclasses
• Immunosuppressants market analysis
  • Market dynamics
  • Key brands analysis
• Anti-rheumatic agents
  • Market dynamics
• Key brands analysis
• Intestinal anti-inflammatory agents
  • Market dynamics
  • Key brands analysis
• IBD sales forecasts to 2012
• Total GIT sales forecasts to 2012

Chapter 3 Pipeline analysis

• Summary
• Introduction
• Key trends in R&D
• Increasing penetration of generics in the GERD/PUD market will continue to
• limit R&D investment
• Continuing, yet uncertain focus on drug development in irritable bowel
• syndrome
• Emerging therapies for the management of inflammatory bowel disease
• New mechanism of action
• The GIT therapeutic area pipeline
• Leading drugs in development
• Profiles of key pipeline products
• Phase II compounds
  • tetomilast (OPC-6535)
  • Alicaforsen (ISIS 2302)
  • OX-17
  • S-tenatoprazole-Na
• Phase III compounds
  • Renzapride
  • Kremezin (AST-120)
  • Cimzia (certolizumab pegol)
  • TAK-390MR (dexlansoprazole)
  • Orencia (abatacept)
• Drugs in registration
  • Ramosetron
• Recently marketed drugs
  • Amitiza (lubiprostone)
• Pipeline forecasts
• Factors affecting forecasts
• GIT pipeline forecasts

Chapter 4 Competitive landscape

• Summary
• Introduction
• Market share
• AstraZeneca
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline
• Strategic analysis
  • Sales and promotions
  • Growth drivers
  • Growth constraints
• Wyeth
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline
• Strategic analysis
  • Sales and promotions
  • Growth drivers
  • Growth constraints
• Abbott
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline
• Strategic analysis
  • Sales and promotions
  • Growth drivers
  • Growth constraints
• Johnson & Johnson
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline
• Strategic analysis
  • Sales and promotions
  • Growth drivers
  • Growth constraints
• Takeda
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline
• Strategic analysis
  • Sales and promotions
  • Growth drivers
  • Growth constraints
• Novartis
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline
• Strategic analysis
  • Sales and promotions
  • Growth drivers
  • Growth constraints
• Astellas
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline
• Strategic analysis
  • Sales and promotions
  • Growth drivers
  • Growth constraints
• Eisai
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline
• Strategic analysis
  • Sales and promotions
  • Growth drivers
  • Growth constraints
• Altana
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline
• Strategic analysis
  • Sales and promotions
  • Growth drivers
  • Growth constraints
• Procter & Gamble
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline
• Strategic analysis
  • Sales and promotions
  • Growth drivers
  • Growth constraints

Chapter 5 Appendix

• IMS data
• Licensing status
• Index
• Index

List of Figures

• Figure 2.1: Global GIT market share by geography, 2006
• Figure 2.2: Licensing status of global GIT sales, 2005-06 ($bn)
• Figure 2.3: Competitive dynamics of the global GIT market by drug class, 2006
• Figure 2.4: Competitive dynamics of the leading 10 brands in the global GIT market, 2005-06
• Figure 2.5: Competitive dynamics of the global GERD/PUD market, 2005-06
• Figure 2.6: Competitive dynamics of the leading 10 brands in the global GERD/PUD market, 2005-06
• Figure 2.7: Competitive dynamics of the global IBS market, 2005-06
• Figure 2.8: Competitive dynamics of the leading 10 brands in the global IBS market, 2005-06
• Figure 2.9: Competitive dynamics of the global IBD market, 2005-06
• Figure 2.10: Competitive dynamics of the leading 10 brands in the global IBD market, 2005-06
• Figure 3.11: Prevailing R&D approaches
• Figure 3.12: The GIT pipeline by indication and stage of development, 2006
• Figure 3.13: Recently launched products and late-stage R&D compounds indicated for the GIT therapeutic area, 2006
• Figure 4.14: Competitive dynamics of the leading players in the global GIT market, 2006
• Figure 4.15: AstraZeneca' s GIT sales, 2006 ($m)
• Figure 4.16: Wyeth' s GIT sales, 2006 ($m)
• Figure 4.17: Abbott' s GIT sales, 2006 ($m)
• Figure 4.18: J&J' s GIT sales, 2006 ($m)
• Figure 4.19: Takeda' s GIT sales, 2006 ($m)
• Figure 4.20: Novartis' GIT sales, 2006 ($m)
• Figure 4.21: Astellas' GIT sales, 2006 ($m)
• Figure 4.22: Eisai' s GIT sales, 2006 ($m)
• Figure 4.23: Altana' s GIT sales, 2006 ($m)
• Figure 4.24: P&G' s GIT sales, 2006 ($m)

List of Tables

• Table 1.1: Estimated prevalence of major GIT indications in the seven major pharmaceutical markets, 2005
• Table 1.2: Estimated prevalence of GERD across the seven major markets, 2006
• Table 1.3: Forecast epidemiology of GERD across the seven major markets, 2006-12
• Table 1.4: Estimated prevalence of PUD in the seven major pharmaceutical markets, 2006
• Table 1.5: Forecast epidemiology of PUD across the seven major markets, 2006-12
• Table 1.6: Estimated prevalence of IBS in the seven major pharmaceutical markets, 2006
• Table 1.7: Forecast epidemiology of IBS across the seven major markets, 2006-12
• Table 1.8: Estimated prevalence of ulcerative colitis in the seven major pharmaceutical markets, 2006
• Table 1.9: Estimated epidemiology of UC across the seven major markets, 2006-12
• Table 1.10: Estimated prevalence of Crohn' s disease in the seven major pharmaceutical markets, 2006
• Table 1.11: Forecast prevalence of Crohn' s disease across the seven major markets, 2006-12
• Table 2.12: Market size ($m) and growth (%) of drug classes within the global GIT market, 2002-06
• Table 2.13: Market size ($m) and growth (%) of leading brands in the global GIT market, 2005-06
• Table 2.14: Market size ($m) and growth (%) of drug classes within the global GERD and PUD market, 2002-06
• Table 2.15: Market size ($m) and growth (%) of leading GERD/PUD products, 2005-06
• Table 2.16: GERD/PUD sales forecast, 2006-12 ($m)
• Table 2.17: Market size (US$) and growth (%) of drug classes within the global IBS market, 2002-06
• Table 2.18: Market size ($m) and growth (%) of leading IBS brands, 2005-06
• Table 2.19: IBS sales forecast, 2006-12 ($m)
• Table 2.20: Market Share ($m) and growth (%) of drug classes within the global IBD market, 2002-06
• Table 2.21: Market size ($m) and growth (%) of leading IBD brands, 2005-06
• Table 2.22: IBD sales forecast, 2006-12 ($m)
• Table 2.23: GIT therapeutic sales forecasts by drug class, 2006-12 ($m)
• Table 3.24: GIT pipeline sales forecasts, 2006-12 ($m)
• Table 4.25: Market share ($m) and growth (%) of leading corporations in the global GIT market, 2005-06
• Table 4.26: AstraZeneca' s GIT portfolio sales, 2005-06 ($m)
• Table 4.27: AstraZeneca' s R&D product pipeline, 2006
• Table 4.28: Promotional spend on major GIT drugs by AstraZeneca, 2005-06 ($m)
• Table 4.29: Wyeth' s GIT portfolio sales, 2005-06 ($m)
• Table 4.30: Wyeth' s R&D product pipeline, 2006
• Table 4.31: Promotional spend on major GIT drugs by Wyeth, 2005-06 ($m)
• Table 4.32: Abbott' s GIT portfolio sales, 2005-06 ($m)
• Table 4.33: Abbott' s R&D product pipeline, 2006
• Table 4.34: Promotional spend on major GIT drugs by Abbott, 2005-06 ($m)
• Table 4.35: J&J' s GIT portfolio sales, 2005-06 ($m)
• Table 4.36: J&J' s R&D product pipeline, 2006
• Table 4.37: Promotional spend on major drugs by J&J, 2005-06 ($m)
• Table 4.38: Takeda' s GIT portfolio sales, 2005-06 ($m)
• Table 4.39: Takeda' s R&D product pipeline, 2006
• Table 4.40: Promotional spend on major drugs by Takeda, 2005-06
• Table 4.41: Novartis' GIT portfolio sales, 2005-06 ($m)
• Table 4.42: Novartis' R&D product pipeline, 2006
• Table 4.43: Promotional spend on major drugs by Novartis, 2005-06 ($m)
• Table 4.44: Astellas' GIT portfolio sales, 2005-06 ($m)
• Table 4.45: Astellas' R&D product pipeline, 2006
• Table 4.46: Promotional spend on major drugs by Astellas, 2005-06
• Table 4.47: Eisai' s GIT portfolio sales, 2005-06 ($m)
• Table 4.48: Eisai' s R&D product pipeline, 2006
• Table 4.49: Promotional spend on major drugs by Eisai, 2005-06
• Table 4.50: Altana' s GIT portfolio sales, 2005-06 ($m)
• Table 4.51: Promotional spend on major drugs by Altana, 2005-06
• Table 4.52: P&G' s GIT portfolio sales, 2005-06 ($m)
• Table 4.53: P&G' s R&D product pipeline, 2006